It's the first drug shown to slow Alzheimer's. Why is is it off to a slow start?
Time:2024-05-21 19:30:37 Source:opinionsViews(143)
The first drug shown to slow Alzheimer’s disease hit the U.S. market over a year ago, but sales have lagged, major hospital systems have taken months to start using it and some insurers have rejected coverage.
Doctors also expect some patients will hesitate to take Leqembi due to its limited impact and potential side effects. They say it will take years to learn how best to deploy the drug and that work must be done to improve diagnosis.
“This is the start of a very exciting journey,” said Dr. Ambar Kulshreshtha, a suburban Atlanta family physician focused on dementia patients.
More than 6 million Americans, and millions more worldwide, have Alzheimer’s disease, the most common cause of dementia. There’s no cure, but Leqembi clears a sticky brain protein called amyloid that’s a key indicator of Alzheimer’s.
Studies showed that it can delay the progression of the disease by a few months when given to people with mild symptoms. Some experts say the delay may be too subtle for patients to notice.
Previous:Medics remove 150 MAGGOTS from a woman's mouth after dental procedure left her with rotting tissue
Next:Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
You may also like
- Pentagon vows to keep weapons moving to Ukraine as Kyiv faces a renewed assault by Russia
- Chris Pine dons plaid blazer to honor his hero Jeff Bridges at 49th Chaplin Award Gala in NYC
- Steve Gleason, 47, reveals his daily 'exorcism' as he battles ALS: Ex
- US judges reject new Louisiana congressional map
- 'The Apprentice,' about a young Donald Trump, premieres in Cannes
- Efficient Real Madrid making an art form of scoring when least expected
- Homeless families face limits on shelter stays as Massachusetts grapples with migrant influx
- Man United makes more executive changes as Jim Ratcliffe's new era takes shape
- Fresh heartache for cancer